The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002

The first large epidemic of meningococcal disease caused by serogroup W135, Burkina Faso, 2002

Abstract In 2001 a significant proportion of cases of meningococcal meningitis toward the end of a serogroup A epidemic in Niger and Burkina Faso was found to be caused by serogroup W135 meningococci. The World Health Organization put in place in several African countries an extended surveillance sc...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine Vol. 25; pp. A37 - A41
Main Authors: Koumaré, Béhima, Ouedraogo-Traoré, Rasmata, Sanou, Idrissa, Yada, Adamou A, Sow, Idrissa, Lusamba, Paul-Samson, Traoré, Etienne, Dabal, Moumouni, Santamaria, Maria, Hacen, Mohamed-Mahmoud, Kaboré, Antoine B, Caugant, Dominique A
Format: Journal Article
Language:English
Published: Netherlands Elsevier Ltd 03-09-2007
Elsevier Limited
Subjects:
Allergy and Immunology
Burkina Faso
Burkina Faso - epidemiology
Disease Outbreaks - history
Epidemic
Epidemics
History, 21st Century
Humans
Immunization
Laboratories
Meningitis
Meningococcal disease
Meningococcal Infections - epidemiology
Meningococcal Infections - history
Neisseria meningitidis
Neisseria meningitidis, Serogroup W-135 - isolation & purification
Niger - epidemiology
Pilgrimages
Population Surveillance - methods
Serogroup W135
Vaccines
Niger
Burkina Faso
Africa
Epidemic
Burkina Faso
Serogroup W135
Meningococcal disease
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract In 2001 a significant proportion of cases of meningococcal meningitis toward the end of a serogroup A epidemic in Niger and Burkina Faso was found to be caused by serogroup W135 meningococci. The World Health Organization put in place in several African countries an extended surveillance scheme in preparation for a possible epidemic situation. In January 2002, the first large epidemic of meningococcal disease caused by serogroup W135 started in Burkina Faso, resulting in more than 12,000 cases and 1400 deaths. We report here the results of the laboratory-based surveillance and the characteristics of the epidemic clone.
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ObjectType-Article-1
ObjectType-Feature-2
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2007.04.038